Active, Not Recruiting
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
NCT04808999
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Neoplasms, +4 more
- Locations
-
- UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States